Pharmaceutics

This page contains key pharmaceutical news on drug recalls, FDA clearance, safety communications and research. In cardiology, key pharmaceutic agents include antiplatelet therapies, anticoagulants, hypertension drugs, and drugs for heart failure and arrhythmias.   

money maze payment reimbursement

Biden chooses semaglutide for next round of Medicare price negotiations—Trump gets final say

The final list also included diabetes drugs sold by Boehringer Ingelheim and Merck. The first round of drug price negotiations reduced the Medicare prices for 10 popular drugs by up to 79%. 

Video of Clyde Yancy, MD, explaining new directions in treating heart failure with preserved ejection fraction.

Exploring the 'new era' of HFpEF treatment: More options exist, but challenges remain

Clyde Yancy, MD, spoke with Cardiovascular Business about how the treatment of heart failure with preserved ejection fraction (HFpEF) has evolved in recent years.

Semaglutide linked to ‘significant and consistent’ benefits for heart bypass surgery patients

The popular GLP-1 receptor agonist appears to help limit adverse events and new-onset diabetes in patients with a history of CABG. Researchers shared the full study in the Journal of the American College of Cardiology.

artificial intelligence pharmaceutical industry

FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

healthcare value value-based care money dollar

Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met. 

Clopidogrel vs. aspirin: Tracking the chronic maintenance period after PCI for different risk groups

As more high-risk patients undergo PCI, what is the best antiplatelet strategy following an initial event-free period of DAPT? Does it change after complex PCI? Researchers aimed to answer these questions, and many others, with new findings published in JAMA Cardiology.

FDA approves new short-term treatment for AFib, atrial flutter in critical care settings

Landiolol, sold by AOP Health under the brand name Rapiblyk, is an intravenous treatment designed to start working right away.

pharmaceutical drug approval process

FDA approves acoramidis, BridgeBio’s new ATTR-CM drug

Acoramidis, a selective transthyretin stabilizer being sold under the brand name Attruby, is now the second ATTR-CM medication to gain FDA approval.

Around the web

Several key trends were evident at the Radiological Society of North America 2024 meeting, including new CT and MR technology and evolving adoption of artificial intelligence.

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.